Company
Adcendo
At Adcendo, we are developing a new generation of antibody-drug conjugates (ADCs) engineered to address cancers with high unmet medical need.
Also known as Adcendo ApS
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Copenhagen, Denmark
- Legal name
- Adcendo ApS
- adcendo.dk (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Adcendo ApS is a clinical-stage biotech company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first- and potential best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs.
Funding snapshot
- Total raised
- $210MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series C, $75M2026-04-14
Funding rounds
- Series C
- $75M2026-04-14, Company stated
- Series B
- $135M2024-11-25, Company stated
Loading relationship preview